中国肺癌杂志
中國肺癌雜誌
중국폐암잡지
CHINESE JOURNAL OF LUNG CANCER
2014年
12期
860-864
,共5页
肺肿瘤%MicroRNAs%EGFR-TKIs%继发性耐药
肺腫瘤%MicroRNAs%EGFR-TKIs%繼髮性耐藥
폐종류%MicroRNAs%EGFR-TKIs%계발성내약
Lung neoplasms%MicroRNAs%EGFR-TKIs%Secondary resistance
近年来，在非小细胞肺癌（non-small cell lung cancer, NSCLC）靶向治疗中，尤其是伴有表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变的患者，EGFR酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）越来越多地进入到临床治疗，但EGFR-TKI耐药的产生不仅影响药物敏感性，甚至出现疾病进展，成为制约其疗效的主要瓶颈。微小RNA（microRNAs, miRNAs）是一种非编码蛋白的RNA，参与转录后水平基因的表达调控，最近研究发现，miRNAs参与了EGFR-TKIs耐药，影响肿瘤细胞对吉非替尼的敏感性。本文就NSCLC中miRNAs与EGFR-TKIs继发性耐药之间的相关性研究进展做简要的综述。
近年來，在非小細胞肺癌（non-small cell lung cancer, NSCLC）靶嚮治療中，尤其是伴有錶皮生長因子受體（epidermal growth factor receptor,EGFR）基因突變的患者，EGFR酪氨痠激酶抑製劑（tyrosine kinase inhibitor, TKI）越來越多地進入到臨床治療，但EGFR-TKI耐藥的產生不僅影響藥物敏感性，甚至齣現疾病進展，成為製約其療效的主要瓶頸。微小RNA（microRNAs, miRNAs）是一種非編碼蛋白的RNA，參與轉錄後水平基因的錶達調控，最近研究髮現，miRNAs參與瞭EGFR-TKIs耐藥，影響腫瘤細胞對吉非替尼的敏感性。本文就NSCLC中miRNAs與EGFR-TKIs繼髮性耐藥之間的相關性研究進展做簡要的綜述。
근년래，재비소세포폐암（non-small cell lung cancer, NSCLC）파향치료중，우기시반유표피생장인자수체（epidermal growth factor receptor,EGFR）기인돌변적환자，EGFR락안산격매억제제（tyrosine kinase inhibitor, TKI）월래월다지진입도림상치료，단EGFR-TKI내약적산생불부영향약물민감성，심지출현질병진전，성위제약기료효적주요병경。미소RNA（microRNAs, miRNAs）시일충비편마단백적RNA，삼여전록후수평기인적표체조공，최근연구발현，miRNAs삼여료EGFR-TKIs내약，영향종류세포대길비체니적민감성。본문취NSCLC중miRNAs여EGFR-TKIs계발성내약지간적상관성연구진전주간요적종술。
In recent years, in non-small cell lung cancer (NSCLC) targeted therapy, especially in patients with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKI) more and more come into the clinical treatment, but EGFR-TKI resistance not only inlfuence the drug sensitivity, appear even disease progression, become the main bottleneck of its curative effect. MicroRNAs (miRNAs) is a non coding RNA and protein involved in regulating gene expression in the transcription level. Recent studies found that miRNAs involved in EGFR-TKIs resistance, which affect the sensitivity of tumor cells to treatment. In this paper, we reviewed brielfy advance in miRNAs and EGFR-TKIs secondary resis-tance research in NSCLC.
